Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials by Haney, Sarah & Hancox, Robert J
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
Respiratory Research
Open Access Research
Overcoming beta-agonist tolerance: high dose salbutamol and 
ipratropium bromide. Two randomised controlled trials
Sarah Haney1,2 and Robert J Hancox*2,3
Address: 1Department of Respiratory Medicine, Sunderland Royal Hospital, Sunderland, UK, 2Department Respiratory Medicine, Waikato 
Hospital, Hamilton, New Zealand and 3Dunedin Multidisciplinary Health and Development Research Unit, Dunedin School of Medicine, 
University of Otago, Dunedin, New Zealand
Email: Sarah Haney - sas_haney@yahoo.co.uk; Robert J Hancox* - bob.hancox@otago.ac.nz
* Corresponding author    
Abstract
Background: Asthmatics treated with long-acting beta-agonists have a reduced bronchodilator
response to moderate doses of inhaled short acting beta-agonists during acute
bronchoconstriction. It is not known if the response to higher doses of nebulised beta-agonists or
other bronchodilators is impaired. We assessed the effect of long-acting beta-agonist treatment on
the response to 5 mg nebulised salbutamol and to ipratropium bromide.
Methods: Two double-blind, placebo-controlled, crossover studies of inhaled formoterol 12 µg
twice daily in patients with asthma.
High-dose salbutamol: 36 hours after the last dose of 1 week of formoterol or placebo treatment,
11 subjects inhaled methacholine to produce a 20% fall in FEV1. Salbutamol 5 mg was then
administered via nebuliser and the FEV1 was monitored for 20 minutes. Ipratropium: 36 hours after
the last dose of 1 week of formoterol or placebo treatment, 11 subjects inhaled 4.5% saline to
produce a 20% fall in FEV1. Salbutamol 200 µg or ipratropium bromide 40 µg was then inhaled and
the FEV1 was monitored for 30 minutes. Four study arms compared the response to each
bronchodilator after formoterol and placebo. Analyses compared the area under the
bronchodilator response curves, adjusting for changes in pre-challenge FEV1, dose of provocational
agent and FEV1 fall during the challenge procedure.
Results: The response to nebulised salbutamol was 15% lower after formoterol therapy compared
to placebo (95% confidence 5 to 25%, p = 0.008). The response to ipratropium was unchanged.
Conclusion: Long-acting beta-agonist treatment induces tolerance to the bronchodilator effect of
beta-agonists, which is not overcome by higher dose nebulised salbutamol. However, the
bronchodilator response to ipratropium bromide is unaffected.
Background
Patients with asthma who are poorly controlled on
inhaled corticosteroids are often prescribed long-acting
beta-agonists [1,2]. However, most asthmatics continue
to need short acting beta-agonists for relief of break-
through symptoms and for treatment during asthma exac-
erbations. Despite accumulating evidence that tolerance
develops to the bronchodilator effects of beta-agonists,
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the effect of regular long-acting beta-agonists on the
response to treatment of exacerbations is rarely consid-
ered in treatment guidelines.
Tolerance to the systemic [3] and bronchoprotective [4]
effects of beta-agonists is known to occur during regular
beta-agonist use. It was previously thought that tolerance
to bronchodilation did not occur. However, recent studies
have shown that tolerance to bronchodilation is easily
demonstrated when tested from a bronchoconstricted
state, such as after methacholine or exercise challenge [5-
13]. Patients using regular long-acting beta-agonists may
therefore be less responsive to further beta-agonist treat-
ment during acute bronchoconstriction. This is poten-
tially a serious problem for patients who are taking these
drugs and experience an exacerbation of asthma.
Studies of bronchodilator tolerance have demonstrated
that regular beta-agonist treatment impairs the bron-
chodilator response to moderate doses of up to 400 µg of
salbutamol [5-12]. It has been suggested that this toler-
ance can easily be overcome by administering higher
doses of beta-agonists, but this has never been formally
examined [14]. Treatment of asthma exacerbations in
emergency departments usually includes higher doses of
beta-agonists given via a nebuliser, typically up to 5 mg
salbutamol [1,2]. There have been no randomised con-
trolled trials of the effects of regular long-acting beta-ago-
nists on this emergency treatment.
It is also unknown whether beta-agonist tolerance use
affects the airway response to other bronchodilators. The
anticholinergic bronchodilator ipratropium bromide is
often added to emergency asthma treatment in severe
bronchoconstriction and in those who respond poorly to
beta-agonist alone [2,15]. It is likely that the bronchodila-
tor response to ipratropium is not affected by prior long-
acting beta-agonist treatment since it acts via a different
receptor. However, beta2-receptors and muscarinic
cholinergic receptors share some intracellular secondary
messengers and their signalling pathways may interact
[16,17]. Hence it is plausible that bronchodilator respon-
siveness to ipratropium could be affected by beta-agonist
tolerance. Moreover, it is possible that beta-agonists have
a non-specific effect on airway smooth muscle tone
thereby altering the response to other bronchodilators
regardless of intracellular signalling pathways [18,19].
Given the role of high dose beta-agonist and ipratropium
bromide in the management of asthma exacerbations, it is
important to assess their effectiveness in the setting of
long-acting beta-agonist treatment. We performed two
studies to address the following questions:
Study 1: Does high dose salbutamol overcome the bron-
chodilator tolerance associated with regular long-acting
beta-agonist use?
Study 2: Does beta-agonist bronchodilator tolerance
affect the bronchodilator response to ipratropium bro-
mide?
Methods
Subjects
Subjects had physician-diagnosed asthma with a provoca-
tive dose to cause a 20% fall in FEV1 (PD20) less than 1.5
mg of methacholine (study 1) or less than 30 ml saline
(study 2) at screening (see below). Subjects were not using
long-acting beta-agonists prior to the study and had not
changed their asthma medications nor had a respiratory
tract infection for 6 weeks prior to study entry. The studies
were approved by the Waikato Ethics Committee. All sub-
jects provided written informed consent.
Study design
Both studies were random-order, double-blind, cross-over
studies comparing formoterol 12 µg twice daily with pla-
cebo. Randomisation was by computer-coded bottles of
identical capsules for use with the Foradil Aeroliser
(Novartis, Auckland, New Zealand). Additional beta-ago-
nists were not allowed throughout the studies. Ipratro-
pium was used for symptom relief.
Study 1: High-dose salbutamol
This was a crossover study with 2 arms. Subjects inhaled
formoterol or placebo twice daily for 1 week. Thirty-six
hours after the last dose, subjects underwent a metha-
choline challenge and salbutamol response as described
below. Subjects then crossed to the other medication for a
repeat sequence of 1 week of treatment, methacholine
challenge and salbutamol response.
Methacholine challenge was performed using a modified
Yan technique [20]. Subjects inhaled doubling doses of
nebulised methacholine until the FEV1 had fallen by ≥
20%. The PD20 methacholine was calculated by linear
interpolation of the last two doses. Immediately after
completion of the methacholine challenge, subjects were
given 5 mg salbutamol via a Sidestream nebuliser and Sys-
tem 22 aerosol mask (Profile, Bognor Regis, UK) powered
by oxygen at a rate of 6 L/minute. FEV1 was measured at 5,
10, 15 and 20 minutes after starting the nebuliser.
Study 2: Ipratropium bromide
This was a crossover study with four arms. For each arm
subjects inhaled formoterol 12 µg or placebo twice daily
for 1 week. Thirty-six hours after the last dose, subjects
underwent a hypertonic saline challenge and bronchodi-
lator response as described below. Subjects then receivedRespiratory Research 2007, 8:19 http://respiratory-research.com/content/8/1/19
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the alternative medication and started the next arm of the
study. Two study arms compared the bronchodilator
response to salbutamol after formoterol and placebo
treatment and the other two arms compared the response
to ipratropium bromide after formoterol and placebo.
Hypertonic saline challenge was performed according to
the method of the European Respiratory Society [21]. Sub-
jects inhaled 4.5% saline until the FEV1 fell by ≥ 20%. The
PD20 saline was calculated by linear interpolation of the
last two doses. Immediately after the challenge, 200 µg
salbutamol or 40 µg ipratropium was given via a metered
dose inhaler and large volume spacer. FEV1 was measured
5, 10, 15, 20 and 30 minutes after the bronchodilator.
Analysis
The main outcome measurement was the area under the
salbutamol or ipratropium response curves (AUC),
expressed as a percentage of the fall in FEV1 induced by
challenge. Comparisons between treatments were
adjusted for baseline FEV1 and dose of provocational
agent given using analysis of covariance. A secondary out-
come for each study was the final post-bronchodilator
FEV1, which was also adjusted for the fall in FEV1 during
challenge. Post hoc comparisons between placebo and
formoterol treatments were were made using Tukey's exact
method. Comparisons of pre-challenge FEV1 and of PD20
were made using paired Student's t-tests. PD20 values were
log-transformed for analysis.
Previous studies indicated that a sample size of 12 sub-
jects would detect a 30% fall in AUC with 80% power at
α = 0.05 [5].
Results
Study 1: High dose salbutamol
Eleven subjects were recruited and completed the study.
Baseline characteristics of the subjects are shown in table
1. There was no significant effect of order of treatment on
AUC, pre-challenge FEV1 or PD20 methacholine. The pre-
challenge FEV1 and PD20 methacholine were not signifi-
cantly different between placebo and formoterol arms
(table 2).
The salbutamol response, expressed as area under the
curve, was 15% lower in the formoterol period compared
to placebo (95% confidence interval 5 to 25%). This was
a significant difference when taking the covariates into
account (p = 0.008) (table 2, figure 1).
The final FEV1 20 minutes after challenge after 5 mg salb-
utamol was 2.67 L in the formoterol arm compared to
2.79 L after placebo (95% CI for difference 0.06 to 0.19 L;
p = 0.003).
Study 2: Ipratropium bromide
Thirteen subjects were recruited to the study. Two subjects
withdrew during the first treatment period, one with
uncontrolled asthma and one with a respiratory infection
(taking formoterol and placebo respectively). Baseline
characteristics are shown in table 1. There was no effect of
order of treatment.
The mean pre-challenge FEV1 and PD20 saline did not
change significantly between formoterol and placebo
arms. However, one subject experienced a less than 15%
fall in FEV1 with inhalation of saline after taking formot-
erol. For analytical purposes, the PD20 saline for these
challenges has been assumed to be 30 ml (the maximum
value available for inhalation). Exclusion of this subject
from analysis does not materially alter the results.
The response to ipratropium, expressed as the AUC, was
not significantly different between formoterol or placebo
treatment arms (table 3, figure 2). The final FEV1, 30 min-
utes after ipratropium was not significantly different
between the formoterol or placebo arms.
The response to salbutamol was reduced in the formoterol
arm compared to placebo. The mean difference in the
AUC was 26% (95% CI 6 to 46%; p = 0.02) (table 3, figure
2). The FEV1 30 minutes after salbutamol was also lower
in the formoterol arm compared to placebo, 2.74 L com-
pared to 2.91 L (95% CI for difference 0.05 to 0.38; p =
0.02 by covariate analysis).
Discussion
These studies confirm that the response to salbutamol is
reduced in subjects taking long-acting beta-agonists. This
Table 1: Baseline characteristics of subjects
Study 1. High dose salbutamol 2. Ipratropium
Number of subjects 11 11
Male 33
Age (range) 37 (22 to 62) 34 (19 to 53)
Number on inhaled steroids Dose range (µg)(budesonide equivalent) 9 (200 to 1200) 10 (200 to 2000)
FEV1% predicted at screening (range) 79 (61 to 101) 86 (65 to 103)Respiratory Research 2007, 8:19 http://respiratory-research.com/content/8/1/19
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reduction in response was evident even when 5 mg salb-
utamol was given via nebuliser. By contrast, the bron-
chodilator response to ipratropium was not affected by
prior use of formoterol.
It is known that tolerance to bronchodilation occurs fol-
lowing regular formoterol. This has usually been demon-
strated by measuring the bronchodilator response to up to
400 µg of salbutamol via metered dose inhaler. In terms
of bronchodilation, 2.5 mg via a nebuliser is equivalent to
800 µg via metered dose inhaler and spacer [22]. We used
a 5 mg dose of nebulised salbutamol in this study as this
is commonly used in the emergency treatment of asthma.
Higher single doses of salbutamol in a nebuliser are not
recommended [2]. We found that the response to 5 mg of
salbutamol was impaired after 1 week of regular formot-
erol use, indicating that patients using long-acting beta-
agonists are likely to respond poorly to first-line treatment
of acute severe asthma even if high doses of nebulised
beta-agonist are used. Although the differences in the
dose-response curves and final FEV1 shown in this study
may appear modest, it has been shown that the degree of
beta-agonist tolerance increases with the degree of bron-
choconstriction [7]. Patients with acute severe asthma will
have much more severe bronchoconstriction than the
20% fall in FEV1 induced in this study [2,23]. They are
therefore likely to have a much greater impairment in
response to beta-agonists. In practice, many patients are
given repeated doses of beta-agonists via nebuliser during
an acute exacerbation. It was not possible to test the effects
of repeated nebulisations using this model owing to the
time taken for nebulisation (around 5 minutes) and the
effect of spontaneous recovery from methacholine-
induced bronchoconstriction.
The findings of the salbutamol study appear to contrast
with those of a study which found no difference in the
response to emergency department beta-agonist treat-
ment between patients who had been taking long-acting
beta-agonists and those who had not [24]. However, this
emergency department study did not assess the preceding
use of short-acting beta-agonists. Since almost all asth-
matics take large doses of beta-agonists before presenting
to hospital [25] and tolerance to beta-agonists develops
rapidly [11], it is highly likely that the 'control' group had
also developed tolerance.
The bronchodilator response to ipratropium bromide was
not impaired by prior use of long-acting beta-agonist. This
confirms that the effect that we have interpreted as beta-
agonist tolerance is specific to beta-agonists and unlikely
to be due to a non-specific change in airway smooth mus-
cle responsiveness. The intracellular effects of both beta-
agonists and cholinergic agents are now known to be far
more complex than action on single second messenger
systems and there are plausible mechanisms of interaction
between them [16,26]. Muscarinic agonists appear to
reduce the potency of beta-agonist bronchodilation, pos-
sibly through an effect on adenylyl cyclase [17]. The con-
verse effect of muscarinic antagonists has been more
Response to high dose salbutamol (n = 11) Figure 1
Response to high dose salbutamol (n = 11).
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Table 2: Results of the high dose salbutamol study (study 1)
Treatment Placebo Formoterol
Pre-challenge FEV1 (L) (SD) 2.55 (0.75) 2.57 (0.72)
Post challenge FEV1 (L) (SD) 1.92 (0.59) 2.00 (0.51)
PD20 methacholine (mg) (geometric mean, 95% CI) 0.08 (0.03, 0.22) 0.10 (0.04, 0.25)
AUC salbutamol (%.time) (SD) 412 (140) 339 (201)
Difference: paired t-test (95% CI) 73 (-4, 149) p = 0.06
Difference: covariate analysis (placebo-formoterol) (least squares means, 95% CI) 63 (22, 105) p = 0.008
Post-salbutamol FEV1 at 20 mins (L) (SD) 2.79 (0.86) 2.67 (0.84)
Difference: paired t-test (95% CI) 0.12 (0.03, 0.20) p = 0.008
Difference: covariate analysis (placebo-formoterol) (least squares means, 95% CI) 0.12 (0.06, 0.19) p = 0.003Respiratory Research 2007, 8:19 http://respiratory-research.com/content/8/1/19
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difficult to assess [27]. Acetylcholine in human airways
acts via muscarinic receptors to decrease cyclic AMP and
reduce intracellular calcium release, thereby causing bron-
choconstriction. Ipratropium blocks these actions,
thereby reducing smooth muscle tone and causing bron-
chodilation. Cyclic AMP is also a key second-messenger in
the response to beta-receptor activation. Regular exposure
to beta-agonists appears to uncouple the beta-receptor
from cAMP production [28]. Therefore it seemed possible
that beta-agonist tolerance would also have an effect on
the response to ipratropium. However, this was not dis-
cernible in our study. The addition of ipratropium bro-
mide to beta-agonist treatment in acute severe asthma
improves bronchodilation [15], whereas it affords little
additional benefit in stable asthma [29]. It is possible that
this is because the response to beta-agonist in severe
asthma is impaired because of prior beta-agonist treat-
ment, whereas the response to anticholinergic treatment
is maintained. In this study the bronchodilator response
to salbutamol was more rapid and greater than to ipratro-
pium bromide, even after tolerance had developed. How-
ever, the effect of beta-agonist tolerance increases with
increasing levels of bronchoconstriction [7]. In severe
asthma the modest response to ipratropium bromide may
become more important.
These studies used formoterol as the long-acting beta-ago-
nist. Studies in the emergency department have focussed
on patients taking salmeterol [24]. Salmeterol is a partial
agonist at the beta-receptor compared to formoterol and
theoretically it may be less likely to induce tolerance.
Alternatively, salmeterol could act as a partial antagonist
to salbutamol and reduce the effects of salbutamol still
further. In practice, trials that have compared bronchodi-
lator tolerance using the challenge-rescue model have not
found any difference between salmeterol and formoterol
[8,10].
We have interpreted the reduction in response to beta-
agonists as tolerance or tachyphylaxis to the effects of
beta-agonists. Downregulation of the beta-receptors both
in terms of receptor number and intracellular response to
receptor stimulation is a pharmacologically predictable
effect of repeated receptor stimulation [28]. An alternative
explanation for the reduced response to beta-agonist is
that some beta-receptors were still occupied by formoterol
molecules at the time of the test and were therefore not
available to bind to salbutamol, reducing its effect. We
measured the bronchodilator response 36 hours after the
last dose of formoterol. This is outside the normal dura-
tion of action of formoterol [30] and receptor occupancy
should be minimal at this time. The 36-hour withdrawal
of formoterol also minimises confounding of the results
by large changes in pre-challenge FEV1  and PD20.
Response to salbutamol and ipratropium bromide (n = 11) Figure 2
Response to salbutamol and ipratropium bromide (n = 11).
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Table 3: Results of the ipratropium study (study 2)
Bronchodilator Ipratropium Salbutamol
Treatment Placebo Formoterol Placebo Formoterol
Pre-challenge FEV1 (L) (SD) 2.77 (0.50) 2.67 (0.41) 2.62 (0.50) 2.67 (0.63)
Post-challenge FEV1(L)(SD) 2.15 (0.38) 2.07 (0.37) 2.06 (0.41) 2.11 (0.60)
PD20 saline (ml) (95% CI) 11.8 (7.4–19) 8.0 (4.6–13.8) 8.9 (4.9–16.0) 8.6 (5.0–14.6)
AUC %.time (SD) 447 (215) 401 (154) 759 (203) 557 (131)
Difference: paired t-test (95% CI) 138 (-48,138) p = 0.303 202 (66, 339) p = 0.008
Difference: covariate analysis (placebo-formoterol) (least squares mean, 95% CI) 88 (-31, 207) p = 0.126 202 (42, 362) p = 0.019
FEV1 at 30 mins (L) (SD) 2.81 (0.54) 2.67 (0.45) 2.91 (0.56) 2.74 (0.64)
Difference: paired t-test (95% CI) 0.22 (0–0.30) p = 0.056 0.10 (-0.05, 0.39) p = 0.117
Difference: covariate analysis (placebo-formoterol) (least squares mean, 95% CI) 0.11 (-0.06, 0.28) p = 0.172 0.22 (0.05, 0.38) p = 0.015Respiratory Research 2007, 8:19 http://respiratory-research.com/content/8/1/19
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Although one subject showed a bronchoprotective effect
at this time, overall there were no significant differences in
the pre-challenge FEV1 or PD20 values. However, it is also
known that beta-receptors recover rapidly following
downregulation [31] and the timing of challenges 36
hours after the last dose of long-acting beta-agonist may
mean that the tolerance measured in these trials was actu-
ally lower than that experienced by patients who continue
take their long-acting beta-agonists twice daily [12].
There are potential limitations to our study design. First,
this challenge-rescue model does not accurately reflect all
of the pathophysiology of acute asthma, where airway
inflammation, oedema and mucus production play
important roles in airway obstruction. Nevertheless, air-
way smooth muscle contraction is important and is the
main target of emergency bronchodilator treatment. In
addition, not all of the subjects in these studies were tak-
ing inhaled corticosteroids, whereas current guidelines
recommend that long-acting beta-agonists are used in
conjunction with inhaled corticosteroids [1,2]. There is
conflicting evidence on whether systemic corticosteroids
may partly reverse tolerance [32]. However, it is known
that stable doses of inhaled corticosteroids do not influ-
ence the development of tolerance [5] and hence the use
of inhaled corticosteroids was not a requirement in our
selection of subjects.
This study is the first to demonstrate that beta-agonist
bronchodilator tolerance can be demonstrated using
hypertonic saline. Most previous studies using the 'chal-
lenge-rescue' technique have used methacholine as the
challenge agent [5-8,10-12,33]. This would have been
inappropriate prior to studying the response to the anti-
cholinergic drug ipratropium. Our findings confirm that
the challenge-rescue model for studying bronchodilator
tolerance works with both direct and indirect challenges.
The bronchial response to hypertonic saline challenge is
closely correlated with the response to exercise challenge
[34]. A suboptimal response to salbutamol after exercise
challenge has also been found when patients use regular
beta-agonists [9].
Conclusion
In summary, these studies confirm that beta-agonist bron-
chodilator tolerance develops during long-acting beta-
agonist treatment. This is not overcome by 5 mg of neb-
ulised salbutamol. The effect is specific to beta-agonists
and does not affect the response to ipratropium bromide.
Patients using long-acting beta-agonists may respond less
well to emergency beta-agonist treatment. Additional
treatment with an alternative bronchodilator should be
considered early in the course of an exacerbation.
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